Clinical Trial Update: Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant [Phase 1, Phase 2]

View source ↗

Summary

Phase 1b/2a randomized double-blind trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of oral SNIPR001 in pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Escherichia Coli Infection
• Hematologic Malignancy

Drugs mentioned

• SNIPR001 (SNIPR001)

Snippet

Sponsor: SNIPR Biome Aps. | Conditions: E Coli Infections, Allogenic Transplant Patients | Phase 1, Phase 2 | Status: RECRUITING